Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: The role of inflammation

World Journal of Gastroenterology

Volumn 20, Issue 14, 2014, Pages 3751-3761

  Lee, Chun Seng ^a,b   Ryan, Elizabeth J ^a,b   Doherty, Glen A ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Chemotherapy; Diarrhea; Immunogenic cell death; Pro inflammatory cytokines; Side effects

Indexed keywords

BEVACIZUMAB; BUDESONIDE; CAPECITABINE; CELECOXIB; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; INFLIXIMAB; IRINOTECAN; KERATINOCYTE GROWTH FACTOR; LAPATINIB; LOPERAMIDE; OCTREOTIDE; OXALIPLATIN; PLACEBO; SORAFENIB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE PROGRESSION; COLORECTAL CANCER; DIARRHEA; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MUCOSA INFLAMMATION; NONHUMAN; PHAGOCYTOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANIMAL; CELL DEATH; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT; INTESTINE MUCOSA; MUCOSITIS; PATHOLOGY; TUMOR RECURRENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL DEATH; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE MODELS, ANIMAL; FLUOROURACIL; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION; INTESTINAL MUCOSA; MUCOSITIS; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS;

EID: 84898451880     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i14.3751     Document Type: Article

References (96)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, cancer incidence and mortality worldwide: IARC cancerbase no. 10 [internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: URL: http://globocan.iarc.fr
2. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009; 59: 366-378[PMID: 19897840 DOI: 10.3322/caac.20038]
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30[PMID: 23335087 DOI: 10.3322/caac.21166]
4. Stein A, Hiemer S, Schmoll HJ. Adjuvant therapy for early colon cancer: current status. Drugs 2011; 71: 2257-2275[PMID: 22085384 DOI: 10.2165/11594490-000000000-00000]
5. Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer 2006; 14: 505-515[PMID: 16601950 DOI: 10.1007/ s00520-006-0055-4]
6. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321-326[PMID: 7847642 DOI: 10.7326/0003-4819-122-5-19950 3010-00001]
7. Clark JW, Sanoff HK. Adjuvant therapy for resected stage III (node-positive) colon cancer. In: Post TW, editor. UpToDate. Waltham, MA: UpToDate, 2012
8. Lucas AS, O'Neil BH, Goldberg RM. A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 2011; 10: 238-244[PMID: 21820973 DOI: 10.1016/j.clcc.2011.06.012]
9. Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21: 2896-2903[PMID: 12885807 DOI: 10.1200/JCO.2003.10.065]
10. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704[PMID: 15987918 DOI: 10.1056/NEJMoa043116]
11. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116[PMID: 19451431 DOI: 10.1200/JCO.2008.20.6771]
12. Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 2009; 63: 239-251[PMID: 18351341 DOI: 10.1007/s00280-008-0732-8]
13. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807[PMID: 11559717]
14. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 2001; 345: 144-15; author reply 146[PMID: 11450666 DOI: 10.1056/ NEJM200107123450213]
15. Wei EK, Giovannucci E, Wu K, Rosner B, Fuchs CS, Willett WC, Colditz GA. Comparison of risk factors for colon and rectal cancer. Int J Cancer 2004; 108: 433-442[PMID: 14648711 DOI: 10.1002/ijc.11540]
16. Sharif S, O'Connell MJ, Yothers G, Lopa S, Wolmark N. FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest 2008; 26: 956-963[PMID: 18798075 DOI: 10.1080/07357900802132550]
17. Díaz-Rubio E, Tabernero J, Gómez-España A, Massutí B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, González-Flores E, Aparicio J, Rivera F, Losa F, Aranda E. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25: 4224-4230[PMID: 17548839 DOI: 10.1200/JCO.2006.09.8467]
18. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113-130[PMID: 17204026 DOI: 10.1111/ j.1365-2559.2006.02549.x]
19. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345[PMID: 15269313 DOI: 10.1056/NEJMoa033025]
20. Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008; 62: 33-41[PMID: 17703303 DOI: 10.1007/ s00280-007-0570-0]
21. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100: 1995-2025[PMID: 15108222 DOI: 10.1002/cncr.20162]
22. Sonis ST, O'Donnell KE, Popat R, Bragdon C, Phelan S, Cocks D, Epstein JB. The relationship between mucosal cyclooxygenase- 2 (COX-2) expression and experimental radiation- induced mucositis. Oral Oncol 2004; 40: 170-176[PMID: 14693241 DOI: 10.1016/S1368-8375(03)00148-9]
23. Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000; 47: 632-637[PMID: 11034578 DOI: 10.1136/gut.47.5.632]
24. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993; 84: 697-702[PMID: 8340259 DOI: 10.1111/j.1349-7006.1993. tb02031.x]
25. Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 2006; 14: 890-900[PMID: 16604351 DOI: 10.1007/s00520-006-0040-y]
26. Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003; 18: 1095-1100[PMID: 12911669 DOI: 10.1046/j.1440-1746.2003.03136.x]
27. Ikuno N, Soda H, Watanabe M, Oka M. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1995; 87: 1876-1883[PMID: 7494232 DOI: 10.1093/jnci/87.24.1876]
28. Bowen JM, Gibson RJ, Cummins AG, Tyskin A, Keefe DM. Irinotecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemother Pharmacol 2007; 59: 337-348[PMID: 16799812 DOI: 10.1007/ s00280-006-0275-9]
29. Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST, Keefe DM. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007; 33: 448-460[PMID: 17507164 DOI: 10.1016/ j.ctrv.2007.03.001]
30. Melo ML, Brito GA, Soares RC, Carvalho SB, Silva JV, Soares PM, Vale ML, Souza MH, Cunha FQ, Ribeiro RA. Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol 2008; 61: 775-784[PMID: 17624531 DOI: 10.1007/ s00280-007-0534-4]
31. Lima-Júnior RC, Figueiredo AA, Freitas HC, Melo ML, Wong DV, Leite CA, Medeiros RP, Marques-Neto RD, Vale ML, Brito GA, Oriá RB, Souza MH, Cunha FQ, Ribeiro RA. Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation. Cancer Chemother Pharmacol 2012; 69: 931-942[PMID: 22101361 DOI: 10.1007/ s00280-011-1780-z]
32. Francini G, Petrioli R, Lorenzini L, Mancini S, Armenio S, Tanzini G, Marsili S, Aquino A, Marzocca G, Civitelli S. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106: 899-906[PMID: 8143995]
33. Harrison SD, Denine EP, Peckham JC. Qualitative and quantitative toxicity of single and sequential sublethal doses of 5-fluorouracil in BDF mice. Cancer Treat Rep 1978; 62: 533-545[PMID: 657150]
34. Pritchard DM, Potten CS, Hickman JA. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res 1998; 58: 5453-5465[PMID: 9850079]
35. Chang CT, Ho TY, Lin H, Liang JA, Huang HC, Li CC, Lo HY, Wu SL, Huang YF, Hsiang CY. 5-Fluorouracil induced intestinal mucositis via nuclear factor-κB activation by transcriptomic analysis and in vivo bioluminescence imaging. PLoS One 2012; 7: e31808[PMID: 22412841 DOI: 10.1371/ journal.pone.0031808]
36. Yasuda M, Kato S, Yamanaka N, Iimori M, Utsumi D, Kitahara Y, Iwata K, Matsuno K, Amagase K, Yabe-Nishimura C, Takeuchi K. Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1133-G1142[PMID: 22403796 DOI: 10.1152/ajpgi. 00535.2011]
37. Mahr S, Neumayer N, Gerhard M, Classen M, Prinz C. IL- 1beta-induced apoptosis in rat gastric enterochromaffinlike cells is mediated by iNOS, NF-kappaB, and Bax protein. Gastroenterology 2000; 118: 515-524[PMID: 10702202 DOI: 10.1016/S0016-5085(00)70257-5]
38. Wu Z, Han X, Qin S, Zheng Q, Wang Z, Xiang D, Zhang J, Lu H, Wu M, Zhu S, Yu Y, Wang Y, Han W. Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-Fluorouracil in a mouse mucositis model. Biomed Pharmacother 2011; 65: 339-344[PMID: 21723691 DOI: 10.1016/ j.biopha.2011.04.013]
39. Wu ZQ, Han XD, Wang Y, Yuan KL, Jin ZM, Di JZ, Yan J, Pan Y, Zhang P, Huang XY, Wang ZG, Zheng Q. Interleukin- 1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice. Cancer Chemother Pharmacol 2011; 68: 87-96[PMID: 20844880 DOI: 10.1007/s00280-010-1451-5]
40. Soares PM, Mota JM, Souza EP, Justino PF, Franco AX, Cunha FQ, Ribeiro RA, Souza MH. Inflammatory intestinal damage induced by 5-fluorouracil requires IL-4. Cytokine 2013; 61: 46-49[PMID: 23107827 DOI: 10.1016/ j.cyto.2012.10.003]
41. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, Yin S, Hill DC, Wiemann B, Starnes CO, Havill AM, Lu ZN, Aukerman SL, Pierce GF, Thomason A, Potten CS, Ulich TR, Lacey DL. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 1998; 58: 933-939[PMID: 9500453]
42. Bullinger KL, Nardelli P, Wang Q, Rich MM, Cope TC. Oxaliplatin neurotoxicity of sensory transduction in rat proprioceptors. J Neurophysiol 2011; 106: 704-709[PMID: 21593386 DOI: 10.1152/jn.00083.2011]
43. Nassini R, Gees M, Harrison S, De Siena G, Materazzi S, Moretto N, Failli P, Preti D, Marchetti N, Cavazzini A, Mancini F, Pedretti P, Nilius B, Patacchini R, Geppetti P. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 2011; 152: 1621-1631[PMID: 21481532 DOI: 10.1016/j.pain.2011.02.051]
44. Nukatsuka M, Saito H, Sakamoto K, Nakagawa F, Uchida J, Kobunai T, Shiraishi K, Takechi T. Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo. Anticancer Res 2012; 32: 2807-2812[PMID: 22753741]
45. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-4921[PMID: 17050875 DOI: 10.1200/JCO.2006.06.7595]
46. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342[PMID: 15175435 DOI: 10.1056/NEJMoa032691]
47. Festino L, Fabozzi A, Manzo A, Gambardella V, Martinelli E, Troiani T, De Vita F, Orditura M, Ciardiello F, Morgillo F. Critical appraisal of the use of regorafenib in the management of colorectal cancer. Cancer Manag Res 2013; 5: 49-55[PMID: 23610528 DOI: 10.2147/CMAR.S34281]
48. Bowen JM, Mayo BJ, Plews E, Bateman E, Stringer AM, Boyle FM, Finnie JW, Keefe DM. Development of a rat model of oral small molecule receptor tyrosine kinase inhibitorinduced diarrhea. Cancer Biol Ther 2012; 13: 1269-1275[PMID: 22895076 DOI: 10.4161/cbt.21783]
49. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465-1471[PMID: 21383294 DOI: 10.1200/JCO.2010.33.6297]
50. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol 2004; 22: 3238-3247[PMID: 15310767 DOI: 10.1200/JCO.2004.11.057]
51. Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology 2013; 84: 6-13[PMID: 23075905 DOI: 10.1159/000342425]
52. Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, Díaz-Rubio E, Gilberg F, Cassidy J. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol 2012; 23: 1190-1197[PMID: 21896539 DOI: 10.1093/annonc/ mdr366]
53. Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Giessen C, Moosmann N, Heinemann V. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer 2011; 105: 206-211[PMID: 21750558 DOI: 10.1038/bjc.2011.227]
54. Hofheinz RD, Heinemann V, von Weikersthal LF, Laubender RP, Gencer D, Burkholder I, Hochhaus A, Stintzing S. Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer 2012; 107: 1678-1683[PMID: 23033005 DOI: 10.1038/bjc.2012.434]
55. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059[PMID: 17704786 DOI: 10.1038/ nm1622]
56. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, Coutant F, Métivier D, Pichard E, Aucouturier P, Pierron G, Garrido C, Zitvogel L, Kroemer G. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-1701[PMID: 16365148 DOI: 10.1084/ jem.20050915]
57. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010; 16: 3100-3104[PMID: 20421432 DOI: 10.1158/1078-0432.CCR-09-2891]
58. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-426[PMID: 17898760 DOI: 10.1038/nature06175]
59. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12: 860-875[PMID: 23151605 DOI: 10.1038/nrc3380]
60. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, Tesniere A, Zitvogel L, Kroemer G. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30: 1147-1158[PMID: 21151176 DOI: 10.1038/onc.2010.500]
61. Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 2014; 21: 39-49[PMID: 23832118 DOI: 10.1038/ cdd.2013.84]
62. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, André F, Tursz T, Kroemer G, Zitvogel L. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220: 47-59[PMID: 17979839 DOI: 10.1111/j.1600-065X.2007.00573.x]
63. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, Mendiboure J, Pignon JP, Jooste V, van Endert P, Ducreux M, Zitvogel L, Piard F, Kroemer G. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-491[PMID: 19881547 DOI: 10.1038/onc.2009.356]
64. Heel RC, Brogden RN, Speight TM, Avery GS. Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs 1978; 15: 33-52[PMID: 342229 DOI: 10.2165/00003495-197815010-00003]
65. Benson AB, Ajani JA, Catalano RB, Engelking C, Kornblau SM, Martenson JA, McCallum R, Mitchell EP, O'Dorisio TM, Vokes EE, Wadler S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22: 2918-2926[PMID: 15254061 DOI: 10.1200/ JCO.2004.04.132]
66. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, Hérait P, Gandia D. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86: 446-449[PMID: 8120919 DOI: 10.1093/jnci/86.6.446]
67. Cascinu S, Bichisao E, Amadori D, Silingardi V, Giordani P, Sansoni E, Luppi G, Catalano V, Agostinelli R, Catalano G. High-dose loperamide in the treatment of 5-fluorouracilinduced diarrhea in colorectal cancer patients. Support Care Cancer 2000; 8: 65-67[PMID: 10650901]
68. Szilagyi A, Shrier I. Systematic review: the use of somatostatin or octreotide in refractory diarrhoea. Aliment Pharmacol Ther 2001; 15: 1889-1897[PMID: 11736719 DOI: 10.1046/ j.1365-2036.2001.01114.x]
69. Farthing MJ. Octreotide in the treatment of refractory diarrhoea and intestinal fistulae. Gut 1994; 35: S5-10[PMID: 8206397 DOI: 10.1136/gut.35.3_Suppl.S5]
70. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil. Eur J Cancer 1992; 28: 482-483[PMID: 1591068 DOI: 10.1016/S0959-8049(05)80082-6]
71. Petrelli NJ, Rodriguez-Bigas M, Rustum Y, Herrera L, Creaven P. Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. Cancer 1993; 72: 1543-1546[PMID: 8348489]
72. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993; 11: 148-151[PMID: 8418225]
73. Zidan J, Haim N, Beny A, Stein M, Gez E, Kuten A. Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol 2001; 12: 227-229[PMID: 11300329 DOI: 10.1023/A:1008372228462]
74. Gebbia V, Carreca I, Testa A, Valenza R, Curto G, Cannata G, Borsellino N, Latteri MA, Cipolla C, Florena M. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs 1993; 4: 443-445[PMID: 8400346 DOI: 10.1097/00001813-199308000-0 0004]
75. Gibson RJ, Keefe DM, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, King EE, Stringer AM, van der Velden WJ, Yazbeck R, Elad S, Bowen JM. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 2013; 21: 313-326[PMID: 23142924 DOI: 10.1007/s00520-012-1644-z]
76. Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, Davis TW, Masferrer JL. Cyclooxygenase-2inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002; 62: 5778-5784[PMID: 12384538]
77. Dy GK, Mandrekar S, Peethambaram PP, Okuno SH, Croghan GC, Hanson LJ, Furth A, Adjei AA. A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer. Cancer Chemother Pharmacol 2005; 56: 623-628[PMID: 15999272 DOI: 10.1007/ s00280-004-0996-6]
78. Villalona-Calero M, Schaaf L, Phillips G, Otterson G, Panico K, Duan W, Kleiber B, Shah M, Young D, Wu WH, Kuhn J. Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients. Cancer Chemother Pharmacol 2007; 59: 23-33[PMID: 16685529 DOI: 10.1007/s00280- 006-0249-y]
79. Travis SP, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ. Once-daily budesonide MMX in active, mildto- moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63: 433-441[PMID: 23436336 DOI: 10.1136/gutjnl-2012-304258]
80. Prantera C, Marconi S. Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity. Therap Adv Gastroenterol 2013; 6: 137-156[PMID: 23503968 DOI: 10.1177/1756283X12473675]
81. Lenfers BH, Loeffler TM, Droege CM, Hausamen TU. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol 1999; 10: 1251-1253[PMID: 10586346]
82. Karthaus M, Ballo H, Abenhardt W, Steinmetz T, Geer T, Schimke J, Braumann D, Behrens R, Behringer D, Kindler M, Messmann H, Boeck HP, Greinwald R, Kleeberg U. Prospective, double-blind, placebo-controlled, multicenter, randomized phase III study with orally administered budesonide for prevention of irinotecan (CPT-11)-induced diarrhea in patients with advanced colorectal cancer. Oncology 2005; 68: 326-332[PMID: 16020959 DOI: 10.1159/000086971]
83. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996; 93: 7911-7916[PMID: 8755576 DOI: 10.1073/pnas.93.15.7911]
84. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000; 47: 112-119[PMID: 10861272 DOI: 10.1136/gut.47.1.112]
85. Prasad R, Alavi K, Schwartz MZ. Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J Pediatr Surg 2000; 35: 357-359[PMID: 10693696 DOI: 10.1016/S0022-3468(00)90040-X]
86. Booth C, Booth D, Williamson S, Demchyshyn LL, Potten CS. Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. Cell Prolif 2004; 37: 385-400[PMID: 15548172 DOI: 10.1111/j.1365-2184.2004.00320.x]
87. Sigalet DL, Wallace LE, Holst JJ, Martin GR, Kaji T, Tanaka H, Sharkey KA. Enteric neural pathways mediate the antiinflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007; 293: G211-G221[PMID: 17395898 DOI: 10.1152/ajpgi.00530.2006]
88. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001; 61: 687-693[PMID: 11212269]
89. Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Saeki T, Tanaka I. The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight. Eur J Pharmacol 2004; 488: 213-218[PMID: 15044053 DOI: 10.1016/j.ejphar.2004.02.019]
90. Tavakkolizadeh A, Shen R, Abraham P, Kormi N, Seifert P, Edelman ER, Jacobs DO, Zinner MJ, Ashley SW, Whang EE. Glucagon-like peptide 2: a new treatment for chemotherapyinduced enteritis. J Surg Res 2000; 91: 77-82[PMID: 10816354 DOI: 10.1006/jsre.2000.5917]
91. Kissow H, Viby NE, Hartmann B, Holst JJ, Timm M, Thim L, Poulsen SS. Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine. Cancer Chemother Pharmacol 2012; 70: 39-48[PMID: 22729158 DOI: 10.1007/s00280-012-1882-2]
92. Kissow H, Hartmann B, Holst JJ, Poulsen SS. Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. Gut 2013; 62: 1724-1733[PMID: 23086829 DOI: 10.1136/ gutjnl-2012-303280]
93. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17: 3553-3559[PMID: 10550154]
94. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351[PMID: 15175436 DOI: 10.1056/NEJMoa032709]
95. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25: 102-109[PMID: 17194911 DOI: 10.1200/JCO.2006.08.1075]
96. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875[PMID: 15939922 DOI: 10.1200/ JCO.2005.07.113]